Latest Oncology News

FDA Places Partial Clinical Hold on Phase 1 Study of NUV-422 in Solid Tumors

FDA Places Partial Clinical Hold on Phase 1 Study of NUV-422 in Solid Tumors

June 27th 2022

Kristi Rosa

The FDA has placed a partial clinical hold on the phase 1/2 NUV-422-02 trial evaluating the selective small molecule CDK2/4/6 inhibitor NUV-422 in patients with solid tumors such as high-grade glioma, hormone receptor–positive advanced breast cancer, and metastatic castration-resistant prostate cancer.

Olaparib Approaches EU Approval for BRCA+, High-Risk Early Breast Cancer

Olaparib Approaches EU Approval for BRCA+, High-Risk Early Breast Cancer

June 27th 2022

Caroline Seymour

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of olaparib for the adjuvant treatment of patients with germline BRCA-mutated, HER2-negative, high-risk, early breast cancer who have received neoadjuvant or adjuvant chemotherapy.

Leukemia Pioneers Chronicle Career Experiences and Milestones

Leukemia Pioneers Chronicle Career Experiences and Milestones

June 27th 2022

OncLive Staff

Drs Karp, Raza, and Le Beau discuss challenges they faced in their early careers as women in leukemia, the ways they overcame those obstacles, and the unique pitfalls and successes they’ve experienced as female physicians.

Anlotinib/Sintilimab Combo Confers Long-Term OS Benefit in Advanced Cervical Cancer

Anlotinib/Sintilimab Combo Confers Long-Term OS Benefit in Advanced Cervical Cancer

June 27th 2022

Jason Harris

The combination of anlotinib and sintilimab was found to provide a long-term survival benefit to patients with previously treated advanced cervical cancer.

CHMP Supports Approval for Trastuzumab Deruxtecan in Metastatic HER2-Positive Breast Cancer

CHMP Supports Approval for Trastuzumab Deruxtecan in Metastatic HER2-Positive Breast Cancer

June 27th 2022

Chris Ryan

The European Medicines Agency’s Committee for Medicinal Products for Human Use recommended the approval of trastuzumab deruxtecan monotherapy for patients with metastatic HER2-positive breast cancer who have received at least 1 prior anti–HER2-based regimen.

Latest Oncology Videos

All Oncology News

Immunotherapy Combinations Contribute to Efficacy and Safety Advances in Genitourinary Cancer Treatment

June 16th 2022

Ashling Wahner

New treatment strategies with immunotherapeutic agents are challenging standards of care and prolonging survival in first and later lines of metastatic urothelial carcinoma, metastatic renal cell carcinoma, and metastatic castration-resistant prostate cancer.

Relapsed/Refractory Multiple Myeloma: Future Directions in Care

June 16th 2022

Luciano J. Costa, MD, PhD

Closing out their discussion on bispecifics in multiple myeloma, expert hematologist-oncologists share practical advice for community physicians alongside their hopes for the future.

Myelofibrosis: Novel Combination Strategies

June 16th 2022

Pankit Vachhani, MD, University of Alabama at Birmingham Hospital

Focusing on novel combination strategies, experts review clinical trial data and consider where these regimens may fall in the myelofibrosis treatment armamentarium.

Quavonlimab/Pembrolizumab Combo Shows Modest Antitumor Activity in Advanced Melanoma

June 16th 2022

Ryan Scott

The combination of quavonlimab and pembrolizumab was found to be generally well tolerated and to have modest antitumor activity in patients with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor, according to data from a phase 1/2 trial (NCT03179436).

Moving Bispecific and CAR T-Cell Therapies to Earlier Lines of Therapy in MM

June 16th 2022

Luciano J. Costa, MD, PhD

Luciano Costa, MD, and Adriana Rossi, MD, consider the possibility of earlier-line bispecific and CAR T-cell therapies in multiple myeloma.

Novel Agents in the Pipeline for Myelofibrosis

June 16th 2022

Pankit Vachhani, MD, University of Alabama at Birmingham Hospital

A comprehensive review of novel agents currently under investigation with a potential role in the myelofibrosis treatment landscape.

Ibrutinib Plus Venetoclax Produces High MRD Negativity Rate in Previously Untreated CLL

June 15th 2022

Kristi Rosa

The addition of venetoclax to ibrutinib resulted in a high rate of minimal residual disease negativity in the blood and marrow of patients with previously untreated chronic lymphocytic leukemia.

Dr. Martin-Broto on MDM2 and P53 in Soft Tissue Sarcoma

June 15th 2022

Javier Martin-Broto, MD, PhD

Javier Martin-Broto, MD, PhD, discusses the role of MDM2 amplification and p53 inactivation in patients with soft tissue sarcoma.

Dr. Martin-Broto on the Ongoing Research of MDM2 Agonists in Soft Tissue Sarcoma

June 15th 2022

Javier Martin-Broto, MD, PhD

Javier Martin-Broto, MD, PhD, discusses the ongoing research of MDM2 agonists in patients with soft tissue sarcoma.

Duvelisib and Oral Azacitidine Under Study With CHO(E)P in Peripheral T-Cell Lymphoma

June 15th 2022

Caroline Seymour

Duvelisib and oral azacitidine are each being studied in combination with CHOP/CHOEP chemotherapy in patients with previously untreated CD30-negative peripheral T-cell lymphoma in the randomized phase 2 Alliance A059102 trial.

Clinical Scenario 1: A 74-Year-Old Man with Locally Advanced Infiltrative Basal Cell Carcinoma

June 15th 2022

Jennifer L. Atlas, MD

Jennifer Atlas, MD, presents the clinical scenario of a man with locally advanced basal cell carcinoma.

Ripretinib Does Not Provide Superior PFS Benefit Over Sunitinib in Second-line GIST, But Shows Better Tolerability

June 15th 2022

Wayne Kuznar

Ripretinib did not result in a significant improvement in progression-free survival over sunitinib in patients with gastrointestinal stromal tumor who were previously treated with imatinib, missing the primary end point of the phase 3 INTRIGUE trial.

Overview of Molecular Testing in Colorectal Cancer

June 15th 2022

Andrea Cercek, MD

Jaclyn Hechtman, MD, provides an overview of the history of molecular testing in colorectal cancer and how testing has evolved.

Neoadjuvant Abemaciclib and Fulvestrant Facilitates High Complete Gross Resection Rate in Low-Grade Serous Cancer

June 15th 2022

Caroline Seymour

The combination of abemaciclib and fulvestrant led to encouraging responses when used as neoadjuvant therapy which translated to high complete gross resection rates in patients with advanced, low-grade serous ovarian, fallopian tube, and peritoneal carcinoma.

Dr Ana Maria Lopez Named Associate Director for Diversity, Equity, and Inclusion at the Sidney Kimmel Cancer Center– Jefferson Health

June 15th 2022

Sidney Kimmel Cancer Center – Jefferson Health

The Sidney Kimmel Cancer Center– Jefferson Health has appointed Ana Maria Lopez, MD, MPH, MACP, FRCP, as Associate Director for Diversity, Equity, and Inclusion.

See All News